Use of Recombinant Mitogillin for Serodiagnosis of Aspergillus fumigatus-Associated Diseases
In a recent article, Weig et al. evaluated an enzyme-linked immunosorbent assay (ELISA), using recombinant mitogillin for the detection of antibodies in patients with Aspergillus fumigatus-associated diseases (3) . The authors reported a good correlation between production of immunoglobulin G (IgG) antibody against mitogillin and clinical diseases, with sensitivities of 100, 64, and 60% for aspergilloma (AO), invasive pulmonary aspergillosis (IPA), and invasive disseminated aspergillosis (IDA), respectively, where the corresponding specificity of the ELISA was 95.4%, using a cutoff value of the mean optical density (OD) of 307 normal blood donor sera plus 2 standard deviations (SD).
Although the apparently high sensitivities of the ELISA look encouraging, we think that the interpretation of the results was misleading due to the choice of a low cutoff value. For rare diseases such as AO, IPA, and IDA, in order to eliminate the false positives, high specificities (over 99%) are desirable. In our recently published articles on ELISA for antibody and antigen detection in patients with penicilliosis marneffei, a cutoff value of the mean plus 10 SD was chosen, for a specificity of 100% (1, 2) . However, in the study of Weig et al., a low cutoff value of the mean plus 2 SD was chosen, leading to a specificity of just 95.4% (3) .
The 1 ) and the corresponding sensitivities of the ELISA using the mean plus 3 SD, the mean plus 4 SD, and the mean plus 5 SD as the cutoff values can be calculated (Table 1 ). In order to achieve a high specificity (over 99%), a cutoff value of at least the mean plus 4 SD or the mean plus 5 SD has to be chosen. At these cutoff values, the corresponding sensitivity of the ELISA for AO would fall to below 90%, whereas those for IPA and IDA would be less than 20%. In fact, it is not surprising to have low sensitivities for IPA and IDA, as patients suffering from invasive aspergillosis are usually severely immunocompromised (4) and production of antibodies is greatly impaired. 
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A test specificity of Ͼ99%, as has been suggested by Woo et al., seems to be an unjustified postulation for the recombinant mitogillin enzyme-linked immunosorbent assay (ELISA), as the test is not designed to screen a large unbiased population (low prevalence of the disease). Instead, invasive aspergillosis (IA) and aspergilloma (AO) are diseases that occur in welldefined risk patients (high prevalence of the disease in the population studied) (2) . Approximately one-third of the patients with acute IA initially show no definitive signs, though a fatal progression rate of the disease becomes manifest (1). Unfortunately, the diagnostic tools developed to date have low sensitivities (2) and antifungal therapy is initiated empirical and belated. The very high mortality rate of IA (Ͼ80 to 90%) could be reduced when a sensitive test system leads to an early diagnosis and well-timed therapy.
The usefulness of the mitogillin ELISA for a given patient at risk depends largely, besides on its specificity and sensitivity, on its positive and negative predictive values and the probability for false-positive and for false-negative test results. The latter test quality-defining parameters are dependent on the prevalence of the disease in the population studied.
The ability of a test to discriminate diseased cases from healthy controls is evaluated using receiver operating characteristic (ROC) curve analysis (3). An index of the test accuracy is the area under the ROC curve. Each point on the ROC plot represents a sensitivity-specificity pair corresponding to a par- a Data are from samples from aspergillosis patients (AO, IPA, and IDA patients [n ϭ 114]) compared to those from healthy volunteers (n ϭ 307) and were generated using the recombinant mitogillin IgG ELISA as the discriminating variable, i.e., a value was considered positive when the test result was greater than the OD value. Table 1 for explanations of the data used to generate the curve. The solid arrow marks the point with the maximal Youden index. The cutoff value used in the study of Weig et al. (4) is indicated with a dashed arrow, and the cutoff value proposed by Woo et al. is indicated with a dotted arrow. ticular cutoff value. A widely used method to determine the cutoff point based on a ROC curve is to maximize the Youden index (5). The ROC plot data allow calculation of the most effective cutoff value, when the prevalence of the disease is ascertained. The frequency of IA is known to be high in risk patients, but it varies substantially from risk group to risk group and from center to center (1). Since there is no "gold standard" in the laboratory diagnosis of IA, the true prevalence of IA in different risk groups is difficult to estimate (2) .
ROC curve analyses of the recombinant anti-mitogillin IgG ELISA were done with data from blood donors (n ϭ 307) and patients suffering from aspergillosis (n ϭ 114); the analytic data were generated using SPSS software (version 10.0.7; SPSS Inc. Headquarters, Chicago, Ill.) ( Fig. 1 and Table 1 ). The ROC curve analyses of our preliminary data show that our simplified approach (the cutoff was the mean optical density [OD] plus 3 SD standard deviations [SD], calculated from blood donors; the borderline was the mean plus 2 SD) was adequate for a first evaluation of the test. For the group of AO patients, the maximal Youden index lies exactly between the positive and borderline cutoff values used in our study. The results of the analysis confirm the usefulness of the recombinant anti-mitogillin antibody ELISA for the diagnosis of A. fumigatus-related diseases (area under ROC curve Ͼ 0.9). The analysis indicate further that it might be possible to define different cutoff values for different patient groups (e.g., OA versus IA) in order to increase the diagnostic accuracy of the test (data not shown). However, in our opinion this should be done in a later study with an extended number of patients from whom reliable data (proven disease) are available.
